Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

NCT00003514 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Merkel Cell Carcinoma
Islet Cell Carcinoma
Neuroendocrine Carcinoma
Pituitary Tumor

Interventions

DRUG: antineoplaston A10
DRUG: antineoplaston AS2-1
PROCEDURE: alternative product therapy
PROCEDURE: biological therapy
PROCEDURE: biologically based therapies
PROCEDURE: cancer prevention intervention
PROCEDURE: complementary and alternative therapy
PROCEDURE: differentiation therapy

Sponsor

Burzynski Research Institute